Clinical Trials Browser

Active not recruiting × Interventional × Has announcements × Clear all

NCT02166463 2026-03-18

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Phase 3 Active not recruiting

600 enrolled 14 charts 1 FDA

Ann Arbor Stage IIB Hodgkin Lymphoma

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT03375320 2026-03-18

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3 Active not recruiting

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05083169 2026-03-18

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 1 FDA

Multiple Myeloma

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

NCT04404283 2026-03-17

ECHELON-3

Phase 3 Active not recruiting

238 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1/2 Active not recruiting

713 enrolled 1 FDA

Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT03748641 2026-03-16

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04710576 2026-03-16

AGAVE-201

Phase 2 Active not recruiting

241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT04640623 2026-03-13

SunRISe-1

Phase 2 Active not recruiting

220 enrolled 1 FDA

Urinary Bladder Neoplasms

NCT04886804 2026-03-13

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Phase 1 Active not recruiting

608 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03145181 2026-03-12

MajesTEC-1

Phase 1/2 Active not recruiting

302 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT03395197 2026-03-12

TALAPRO-2

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

NCT03399799 2026-03-12

MonumenTAL-1

Phase 1 Active not recruiting

279 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT04557098 2026-03-12

MajesTEC-1

Phase 2 Active not recruiting

194 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT05099172 2026-03-12

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Phase 1/2 Active not recruiting

370 enrolled 1 FDA

Advanced Non-small Cell Lung Cancer

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 3 Active not recruiting

733 enrolled 21 charts 2 FDA

Ovarian Neoplasms

NCT04971226 2026-03-10

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3 Active not recruiting

406 enrolled 18 charts 1 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05091567 2026-03-10

IMforte

Phase 3 Active not recruiting

660 enrolled 23 charts 1 FDA

Small Cell Lung Carcinoma

NCT03336333 2026-03-09

SEQUOIA

Phase 3 Active not recruiting

590 enrolled 12 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT03036098 2026-03-06

CheckMate901

Phase 3 Active not recruiting

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT02362594 2026-03-05

MK-3475-054

Phase 3 Active not recruiting

1,019 enrolled 16 charts 1 FDA

Melanoma

NCT04494425 2026-03-04

DB-06

Phase 3 Active not recruiting

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT03625037 2026-03-03

EPCORE™ NHL-1

Phase 1/2 Active not recruiting

666 enrolled 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03701334 2026-03-03

NATALEE

Phase 3 Active not recruiting

5,101 enrolled 2 FDA

Breast Neoplasms

NCT01362803 2026-03-02

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Phase 1/2 Active not recruiting

99 enrolled 3 FDA

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT03521154 2026-02-27

LAURA

Phase 3 Active not recruiting

216 enrolled 25 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03875235 2026-02-27

TOPAZ-1

Phase 3 Active not recruiting

810 enrolled 24 charts 1 FDA

Gastrointestinal

Biliary Tract Neoplasms

NCT02716116 2026-02-25

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Phase 1/2 Active not recruiting

334 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-02-25

PAPILLON

Phase 3 Active not recruiting

308 enrolled 12 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT04689828 2026-02-20

PSMAfore

Phase 3 Active not recruiting

469 enrolled 11 charts 1 FDA

Prostatic Neoplasms

NCT04039607 2026-02-19

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Phase 3 Active not recruiting

635 enrolled 1 FDA

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT02032823 2026-02-17

OlympiA

Phase 3 Active not recruiting

1,836 enrolled 20 charts 1 FDA

Breast Neoplasms

NCT03504397 2026-02-13

Spotlight

Phase 3 Active not recruiting

565 enrolled 63 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04497844 2026-02-13

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT02213926 2026-02-10

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Phase 2 Active not recruiting

124 enrolled 10 charts 1 FDA

Lymphoma, Mantle-Cell

NCT03710603 2026-02-10

Perseus

Phase 3 Active not recruiting

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Phase 3 Active not recruiting

310 enrolled 18 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03274492 2026-02-06

POLARIX

Phase 3 Active not recruiting

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03653507 2026-02-06

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04044768 2026-02-06

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

52 enrolled 15 charts 1 FDA

Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT04395677 2026-02-06

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Phase 2 Active not recruiting

173 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung